AstraZeneca spins out 6 drugs and an R&D group into Viela Bio, which emerges with a pivotal program and $250M
AstraZeneca $AZN has culled its pipeline of preclinical through mid-stage anti-inflammatory/autoimmune drugs at its big MedImmune subsidiary in Gaithersburg, MD and spun out six programs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
